Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) reported $157 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 17.2%. EPS of -$0.61 for the same period compares to -$0.95 a year ago.The reported revenue represents a surprise of +21.23% over the Zacks Consensus Estimate of $129.51 million. With the consensus EPS estimate being -$1.15, the EPS surprise was +46.96%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Total research and development revenue: $41 million compared to the $25.04 million average estimate based on nine analysts.Product sales, net: $32 million compared to the $24.47 million average estimate based on eight analysts.Revenue- Commercial revenue- SPINRAZA royalties: $56 million versus $55.53 million estimated by eight analysts on average.Revenue- Research and development revenue- Collaborative agreement revenue: $31 million versus $17.79 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -31.1% change.Revenue- Commercial revenue- WAINUA royalties: $13 million versus the seven-analyst average estimate of $12.16 million. The reported number represents a year-over-year change of +142%.Commercial revenue- Royalty revenue- Other royalties: $7 million compared to the $5.55 million average estimate based on seven analysts.Revenue- Total commercial revenue: $116 million compared to the $100.59 million average estimate based on seven analysts. The reported number represents a change of +52.6% year over year.Revenue- Commercial revenue- Other commercial revenue: $8 million versus the six-analyst average estimate of $7.93 million. The reported number represents a year-over-year change of -39.2%.View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have returned +12.5% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks